Shanghai Zedeman Pharmaceutical Technology Co. Ltd. has identified aryl hydrocarbon receptor (AhR) agonists reported to be useful for the treatment of autoimmune disease, cancer, diabetes, eye disorders, viral infections, psoriasis, and inflammatory and neurological disorders, among others.